Keywords: Sanofi-Aventis, Multaq, Bond offer

Sanofi-Aventis’ Multaq less effective than amiodarone, says US researchers, but firm still recommended by SEB analysts

Article | 09 April 2010

Print This

An article in the Journal of the American College of Cardiology has suggested that the use of French drug major ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in